Table 1.
Baseline characteristics of included studies
| Reference | Year | Country | Number (male/female) | Age (years)a | Tumor stageb | Sampling time | Cutoff | Positive rate, n (%) | End point | Treatment regimens | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hiraiwa et al23 | 2008 | Japan | 27 (NR) | NR | IV | Intra-therapy | ≥2/7.5 mL | 15 (55.6) | OS | Chemotherapy | Low |
| Matsusaka et al29 | 2010 | Japan | 52 (44/8) | 62 (24–78) | IV | Baseline | ≥4/7.5 mL | 17 (32.7) | OS, PFS | Chemotherapy | High |
| 51 (NR) | NR | Intra-therapy (2 weeks) | ≥4/7.5 mL | 7 (17.3) | OS, PFS | ||||||
| 48 (NR) | NR | Intra-therapy (4 weeks) | ≥4/7.5 mL | 9 (18.8) | OS, PFS | ||||||
| Uenosono et al28 (1) (training set) | 2013 | Japan | 148 (99/49) | NR | I–III | Baseline | ≥1/7.5 mL | 16 (10.8) | OS, PFS | Surgery | High |
| Uenosono et al28 (2) (validation set) | 2013 | Japan | 103 (NR) | NR | IV | Baseline | ≥1/7.5 mL | 62 (61.8) | OS | Chemotherapy | High |
| Sclafani et al27 | 2014 | UK | 18 (16/2) | 61 (38–78) | IV | Baseline | ≥2/7.5 mL | 8 (44.4) | OS, PFS | Chemotherapy | Low |
| Lee et al25 | 2015 | Korea | 95 (63/32) | 57 (36–85) | IV | Baseline | ≥5/7.5 mL | 27 (28.4) | OS, PFS | Chemotherapy | High |
| Okabe et al26 | 2015 | Japan | 136 (87/49) | NR | I–IV | Baseline | ≥1/7.5 mL | 25 (18.4) | OS, PFS | Surgery + chemotherapy | High |
| Li et al24 | 2016 | China | 136 (89/47) | 59 (25–80) | IV | Baseline | ≥3/7.5 mL | 57 (41.9) | OS, PFS | Chemotherapy | High |
| 106 (NR) | NR | Intra-therapy | ≥3/7.5 mL | 26 (24.5) | OS, PFS |
Notes:
a
Median (range).
b
The seventh edition of the AJCC cancer staging.
Abbreviations: AJCC, American Joint Committee on Cancer; NR, not reported; OS, overall survival; PFS, progression-free survival.